Lixte Biotechnology Holdings Inc (LIXTW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXTW) has a cash flow conversion efficiency ratio of -0.189x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-926.75K) by net assets ($4.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LIXTW stock market capitalisation for the company's overall valuation and market capitalisation.
Lixte Biotechnology Holdings Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Lixte Biotechnology Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lixte Biotechnology Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lixte Biotechnology Holdings Inc ranked by their cash flow conversion efficiency. Explore Lixte Biotechnology Holdings Inc (LIXTW) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pathkey.ai Ltd
AU:PKY
|
2.310x |
|
Spiritus Mundi PLC
LSE:SPMU
|
N/A |
|
Biocept Inc.
NASDAQ:BIOCQ
|
-10.641x |
|
Keras Resources PLC
LSE:KRS
|
-0.132x |
|
Ordinary Fully Paid Deferred Settlement
AU:EDEDA
|
-1.051x |
|
Carbon Revolution Public Limited Ordinary Shares
NASDAQ:CREV
|
0.137x |
|
Pyxis Tankers Inc
NASDAQ:PXSAW
|
0.033x |
|
Shineco Inc
NASDAQ:SISI
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Lixte Biotechnology Holdings Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Lixte Biotechnology Holdings Inc from 2005 to 2024. View LIXTW share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $827.22K | $-3.16 Million | -3.826x | -255.95% |
| 2023-12-31 | $3.99 Million | $-4.29 Million | -1.075x | -20.37% |
| 2022-12-31 | $5.17 Million | $-4.61 Million | -0.893x | -3.24% |
| 2021-12-31 | $4.79 Million | $-4.14 Million | -0.865x | -103.37% |
| 2020-12-31 | $5.01 Million | $-2.13 Million | -0.425x | +38.17% |
| 2019-12-31 | $2.43 Million | $-1.67 Million | -0.688x | -87.80% |
| 2018-12-31 | $4.13 Million | $-1.51 Million | -0.366x | +74.19% |
| 2017-12-31 | $995.04K | $-1.41 Million | -1.419x | +81.83% |
| 2016-12-31 | $214.76K | $-1.68 Million | -7.811x | -11.85% |
| 2015-12-31 | $312.33K | $-2.18 Million | -6.983x | -13.52% |
| 2014-12-31 | $265.86K | $-1.64 Million | -6.152x | -23.17% |
| 2013-12-31 | $236.27K | $-1.18 Million | -4.995x | -518.00% |
| 2012-12-31 | $1.49 Million | $-1.21 Million | -0.808x | +95.30% |
| 2011-12-31 | $79.02K | $-1.36 Million | -17.206x | -3090.42% |
| 2010-12-31 | $1.74 Million | $-936.39K | -0.539x | -9.91% |
| 2009-12-31 | $1.30 Million | $-638.44K | -0.491x | -126.56% |
| 2008-12-31 | $-323.55K | $-597.69K | 1.847x | +199.06% |
| 2007-12-31 | $376.93K | $-702.87K | -1.865x | -163.47% |
| 2006-12-31 | $626.56K | $-443.45K | -0.708x | -116.94% |
| 2005-12-31 | $-7.87K | $-32.87K | 4.177x | -- |
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubi… Read more